FAAS
TVRD

First Allied Advisory Services’s Tvardi Therapeutics TVRD Stock Holding History

First Allied Advisory Services’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$224K Buy
+488
New +$283K 0.01% 1028
2019
Q4 		– Sell
-583
Closed -$382K – 1636
2019
Q3 		$382K Buy
+583
New +$485K 0.01% 796

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Allied Advisory Services's TVRD Position: Q3 2020 in Review

First Allied Advisory Services opened a new position in Tvardi Therapeutics (TVRD) in Q3 2020: 488 shares worth $224K. The stake represents 0.01% of the portfolio and ranks #1028 among its holdings. This is a return to the name: First Allied Advisory Services previously reported a position in TVRD as recently as Q3 2019.

First Allied Advisory Services first reported a position in TVRD in Q3 2019 and has held it in 2 quarters since. The position peaked at $382K in Q3 2019. 160 funds tracked by Wall St. Rank hold TVRD as of Q3 2020.

  • First Allied Advisory Services held 488 shares of Tvardi Therapeutics worth $224K as of Q3 2020.
  • Tvardi Therapeutics was a new First Allied Advisory Services position in Q3 2020.
  • Tvardi Therapeutics made up 0.01% of First Allied Advisory Services's portfolio in Q3 2020, its #1028 holding.
  • First Allied Advisory Services first reported a position in Tvardi Therapeutics in Q3 2019 and has held it in 2 quarters since.
  • First Allied Advisory Services's Tvardi Therapeutics position peaked at $382K in Q3 2019.
  • 160 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2020.

Based on First Allied Advisory Services's 13F filing for Q3 2020, filed 13 Nov 2020.